← Leaderboards
Bruce G Pollock
University Of Pittsburgh At Pittsburgh
$6,203,719
Attributed
$6,203,719
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $804.1K · FY2005–08$1M$750K$500K$250K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$6,203,719 · 7
By mechanism
R01$5,011,645 · 3
K24$615,950 · 1
M01$378,294 · 1
K02$197,830 · 1
P30$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Charles F Reynolds$34,949,629
- Ervin Sejdic$3,064,413
- Andrew F. Stewart$27,613,128
- David A. Brent$43,681,034
- Ellen M Whyte$4,509,175
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectPharmacokineticsAntipsychotic AgentsDementiaSerotonin InhibitorHuman Therapy EvaluationMental Disorder ChemotherapyClinical TrialsAntidepressantsPsychopharmacologyBehavioral /Social Science Research TagAlzheimer'S DiseaseClinical ResearchRisperidoneAnxietyHuman Old Age (65+)Outcomes ResearchTherapy CompliancePatient Oriented ResearchIsozymesMajor DepressionRelapse /RecurrenceAgingDrug Adverse Effect
Grant awards (30)
Maintenance Therapies in Late-Life Depression-III$615,139
R01 · FY2008 · MH · contact PI
Maintenance Therapies in Late-Life Depression-III$629,720
R01 · FY2007 · MH · contact PI
Maintenance Therapies in Late-Life Depression-III$650,538
R01 · FY2006 · MH · contact PI
Geropsychopharmacology: Enhancing Benefit, Reducing Risk$128,960
K24 · FY2006 · MH · contact PI
Maintenance Therapies in Late-Life Depression-III$666,094
R01 · FY2005 · MH
Geropsychopharmacology: Enhancing Benefit, Reducing Risk$125,990
K24 · FY2005 · MH
CONTINUATION PHARMACOTHERAPY FOR AGITATION OF DEMENTIA$11,992
M01 · FY2005 · RR
Continuation Pharmacotherapy for Agitation of Dementia$366,302
M01 · FY2004 · RR
CONTINUATION PHARMACOTHERAPY FOR AGITATION OF DEMENTIA$299,672
R01 · FY2004 · MH
Atypical Antipsychotics: Determinants of Concentration$260,035
R01 · FY2004 · MH
Geropsychopharmacology: Enhancing Benefit, Reducing Risk$123,105
K24 · FY2004 · MH
CONTINUATION PHARMACOTHERAPY FOR AGITATION OF DEMENTIA$290,936
R01 · FY2003 · MH
Atypical Antipsychotics: Determinants of Concentration$261,742
R01 · FY2003 · MH
Geropsychopharmacology: Enhancing Benefit, Reducing Risk$120,307
K24 · FY2003 · MH
CONTINUATION PHARMACOTHERAPY FOR AGITATION OF DEMENTIA$279,146
R01 · FY2002 · MH
Atypical Antipsychotics: Determinants of Concentration$263,439
R01 · FY2002 · MH
Geropsychopharmacology: Enhancing Benefit, Reducing Risk$117,588
K24 · FY2002 · MH
CORE--GERIATRIC PSYCHOPHARMACOLOGY$0
P30 · FY2002 · MH
CORE--GERIATRIC PSYCHOPHARMACOLOGY$0
P30 · FY2002 · MH
SEROTONERGIC PHARMACOTHERAPY FOR AGITATION OF DEMENTIA$0
M01 · FY2002 · RR
SEROTONERGIC PHARMACOTHERAPY FOR AGITATION OF DEMENTIA$0
M01 · FY2002 · RR
Atypical Antipsychotics: Determinants of Concentration$277,704
R01 · FY2001 · MH
CONTINUATION PHARMACOTHERAPY FOR AGITATION OF DEMENTIA$265,353
R01 · FY2001 · MH
GEROPSYCHOPHARMACOLOGY--ENHANCING BENEFIT, REDUCING RISK$98,915
K02 · FY2001 · MH
CORE--GERIATRIC PSYCHOPHARMACOLOGY$0
P30 · FY2001 · MH
SEROTONERGIC PHARMACOTHERAPY FOR AGITATION OF DEMENTIA$0
M01 · FY2001 · RR
CONTINUATION PHARMACOTHERAPY FOR AGITATION OF DEMENTIA$252,127
R01 · FY2000 · MH
GEROPSYCHOPHARMACOLOGY--ENHANCING BENEFIT, REDUCING RISK$98,915
K02 · FY2000 · MH
CORE--GERIATRIC PSYCHOPHARMACOLOGY$0
P30 · FY2000 · MH
SEROTONERGIC PHARMACOTHERAPY FOR AGITATION OF DEMENTIA$0
M01 · FY2000 · RR